Home/Pipeline/Antral Gastroplasty / Endoscopic Sleeve

Antral Gastroplasty / Endoscopic Sleeve

Obesity

Pre-clinicalActive

Key Facts

Indication

Obesity

Phase

Pre-clinical

Status

Active

Company

Endo-TAGSS

About Endo-TAGSS

Endo-TAGSS is a private, pre-revenue medical device company founded in 2016 and based in San Diego, CA, USA. Its core technology is the TAGSS device, a 12mm trans-abdominal gastric port system intended to bridge the gap between endoscopy and laparoscopy, allowing for more complex intragastric surgeries with fewer incisions and potentially lower costs. The company is in the pre-clinical stage, having demonstrated proof-of-concept in animal models for applications like pyloroplasty and fundoplication, but its devices are not yet FDA-cleared for sale.

View full company profile

Therapeutic Areas

Gastroenterology Oncology Metabolic Disorders

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
RGT-075	Regor Therapeutics	Phase 2b	Active
Anti‑Obesity Oral Drug	Premas Biotech	Phase 1	Active
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Undisclosed siRNA Programs	Moonwalk Biosciences	Pre-clinical	Active